Dr. Lisa Sterman holds up a Truvada pill at her office in San Francisco. – AP
Dr. Lisa Sterman holds up a Truvada pill at her office in San Francisco. – AP

WASHINGTON: Drugmaker Gilead Sciences Inc. says federal health regulators have delayed a decision on whether to approve its drug Truvada as the first pill that prevents HIV infection.

Gilead Sciences said Friday the Food and Drug Administration will take an additional three months to review its drug application, after the California company submitted additional materials to the agency earlier this month.

In May, a panel of experts recommended approval of the daily pill Truvada for healthy people who are at high risk of contracting HIV. The group's vote is nonbinding, but the FDA often follows its advice.

Gilead says it submitted updated details on its safety materials for patients and doctors using Truvada. The FDA typically extends its reviews after receiving such information.

More From This Section

Erdogan challenges social media in top Turkish court

The Twitter block was lifted earlier this month after the court ruled that it breached freedom of expression.

Health care site flagged in heartbleed review

Password change recommended following a review of the government's vulnerability to Heartbleed Internet security flaw.

White House updating online privacy policy

A new privacy policy explains how the government will gather the user data of online visitors to WhiteHouse.gov

Local drugmakers cashing in on MNCs’ departure

Some seven local pharmaceuticals have already inititated projects costing Rs3 billion to Rs5bn in the last 2-3 years.


Comments are closed.
Explore: Indian elections 2014
Explore: Indian elections 2014
How much do you know about Indian Elections?
How much do you know about Indian Elections?
Poll
From The Newspaper
Tweets